论文部分内容阅读
目的探讨注射用重组人白介素-11(rh IL-11)治疗吉西他滨化疗所致血小板减少的临床效果。方法选取2014年10月至2016年12月间武汉大学人民医院收治的112例吉西他滨化疗所致血小板减少患者,根据患者意愿(是否同意使用rh IL-11)将其分入观察组和对照组,观察组67例,对照组45例。观察组患者采用rh IL-11治疗,对照组患者采用氨肽素治疗,比较两组患者治疗前及治疗7d后的血小板(PLT)水平、达标例数和达标时间,比较两组患者的临床疗效和不良反应。结果观察组与对照组PLT达标率分别为94.0%和75.6%,达标时间分别为(6.12±1.27)d和(9.65±2.86)d,差异均有统计学意义(均P<0.05);观察组患者总有效率为94.0%,高于对照组患者的75.6%,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论 rh IL-11治疗吉西他滨化疗所致血小板减少有较好的临床疗效,血小板达标所需时间较短,效率较高,优于一般性升血小板药物。
Objective To investigate the clinical effect of injecting recombinant human interleukin-11 (rh IL-11) on gemcitabine-induced thrombocytopenia. Methods A total of 112 patients with thrombocytopenia induced by gemcitabine chemotherapy were enrolled from the People’s Hospital of Wuhan University from October 2014 to December 2016. Patients were divided into observation group and control group according to their wishes (whether or not they agreed to use rh IL-11) 67 cases in the observation group and 45 cases in the control group. The patients in the observation group were treated with rh IL-11, and the patients in the control group were treated with aminopeptin. The levels of platelet (PLT) before treatment and after 7 days of treatment were compared between the two groups And adverse reactions. Results The compliance rates of PLT in observation group and control group were 94.0% and 75.6%, respectively, and the compliance time was (6.12 ± 1.27) d and (9.65 ± 2.86) d, respectively, with statistical significance (all P <0.05) The total effective rate was 94.0%, higher than that of the control group (75.6%), the difference was statistically significant (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusions rh IL-11 has a good clinical efficacy in the treatment of gemcitabine-induced thrombocytopenia. The required time for platelet to reach the standard is shorter and the efficiency is higher, which is better than that of general platelet drugs.